Viking Therapeutics, Inc.
VKTX
株式のランク
#4532
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
株価
$26.38
最終同期: 2026-10-21
時価総額
$3.35B
変化（1日）
-1.23%
変化（1年）
-16.04%
国
US
取引 Viking Therapeutics, Inc. (VKTX)
カテゴリー
Healthcare
Viking Therapeutics, Inc.（VKTX）の株価履歴
終値の最高値: $27.60 （2026-10-01）
終値の最安値: $8.59 （2015-04-01）
終値の最安値: $8.59 （2015-04-01）
Viking Therapeutics, Inc. の株価履歴（2015 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -7.84% |
| 2025 | -20.83% |
| 2024 | 152.59% |
| 2023 | 215.71% |
| 2022 | 16.84% |
| 2021 | -21.08% |
| 2020 | -20.48% |
| 2019 | -10.51% |
| 2018 | 130.53% |
| 2017 | 246.93% |
| 2016 | -60.36% |
| 2015 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
